Conf. dr. Cristinel MORTICI, Universitatea "Valahia" din Târgovişte
Din Syafrudin DR
-
Upload
ricky-pebriansyah -
Category
Documents
-
view
86 -
download
4
description
Transcript of Din Syafrudin DR
MOLECULAR BASIS OFANTIMALARIAL DRUG RESISTANCE:
Saving our last arsenal, artemisinin
D. SyafruddinEijkman Institute for Molecular Biology, Jakarta
Life Cycle of the malarial parasitePlasmodium spp
101111 haploid parasites in acuteinfection
Re-assortment and recombinationoccur in sexual cycle to producenew resistant genotype in eachgeneration
EIJKMAN INSTITUTE
Whenever drug treatment isrequired to control pathogen,selection of drug resistance isInevitable (Peters, 1987)
101111 haploid parasites in acuteinfection
Re-assortment and recombinationoccur in sexual cycle to producenew resistant genotype in eachgeneration
What is drug resistance:“ The ability of a parasite strain to multiply or survive in thepresence of concentrations of drug that normally destroyparasite of the same species or prevent their multiplication”(Bruce-Chwatt et al, 1986)
Clinical classification (WHO, 2003)
Early treatment failure (ETF):Aggravation or persistence of symptoms in the presence ofparasitaemia during the first 3 days
Late treatment failure (LTF):Reappearance of symptoms in the presence of parasitaemia during days 4-14
Adequate clinical/Parasitological response (ACPR):Absence of parasitaemia on the day 14 irrespective of fever, or absenceof clinical symptoms irrespective of parasitaemia, in patients notmeeting ETF or LTF criteria
EIJKMAN INSTITUTE
Clinical classification (WHO, 2003)
Early treatment failure (ETF):Aggravation or persistence of symptoms in the presence ofparasitaemia during the first 3 days
Late treatment failure (LTF):Reappearance of symptoms in the presence of parasitaemia during days 4-14
Adequate clinical/Parasitological response (ACPR):Absence of parasitaemia on the day 14 irrespective of fever, or absenceof clinical symptoms irrespective of parasitaemia, in patients notmeeting ETF or LTF criteria
Major achievements of WHO'scoordination and global database on
drug efficacy77 endemic countrieschanged drug policy basedon the results of theirtherapeutic efficacy testsReport on global monitoringGFATM changed choice ofdrug procurementDetection of artesunateresistance at Thai-Cambodia border
77 endemic countrieschanged drug policy basedon the results of theirtherapeutic efficacy testsReport on global monitoringGFATM changed choice ofdrug procurementDetection of artesunateresistance at Thai-Cambodia border
Countries which need ACT policyCountries which adopted ACT
EIJKMAN INSTITUTE
Consequences of antimalarialdrug resistance
Increased morbidity and mortalityincluding anaemia, low birth weight,
Increased of transmissionswitch to effective drug combinations in situations of low tomoderate endemicity has always resulted in a dramaticdecrease in transmission
Economic impactincreases cost to health services (to both provider andpatient) because of returning treatment failures
Greater frequency and severity of epidemicsModification of malaria distributionGreater reliance on informal private sector
with the risk of using monotherapies, sub-standard andcounterfeit medicines which in turn will increase drug resistance
Increased morbidity and mortalityincluding anaemia, low birth weight,
Increased of transmissionswitch to effective drug combinations in situations of low tomoderate endemicity has always resulted in a dramaticdecrease in transmission
Economic impactincreases cost to health services (to both provider andpatient) because of returning treatment failures
Greater frequency and severity of epidemicsModification of malaria distributionGreater reliance on informal private sector
with the risk of using monotherapies, sub-standard andcounterfeit medicines which in turn will increase drug resistance
EIJKMAN INSTITUTE
Introduced First Report Differenceof Resistance (years)
Quinine 1632 1910 278Chloroquine 1945 1957 12Proguanil 1948 1949 1Sulphadoxine- 1967 1967 0pyrimethamineMefloquine 1977 1982 5Atovaquone 1996 1996 0Artemisinin 2000 ?
History of antimalarial drug resistance
EIJKMAN INSTITUTE
Introduced First Report Differenceof Resistance (years)
Quinine 1632 1910 278Chloroquine 1945 1957 12Proguanil 1948 1949 1Sulphadoxine- 1967 1967 0pyrimethamineMefloquine 1977 1982 5Atovaquone 1996 1996 0Artemisinin 2000 ?
EIJKMAN INSTITUTE
EIJKMAN INSTITUTE
Antimalarial drugs and their predictedtarget sites
EIJKMAN INSTITUTE
Recommended Artemisinin-basedCombination Therapy (ACTs) WHO 2010
Artemether+lumefantrine*Artesunate+amodiaquine*Artesunate+mefloquineArtesunate+sulphadoxine-pyrimethamineDihydroartemisinin+piperaquine*
Artemether+lumefantrine*Artesunate+amodiaquine*Artesunate+mefloquineArtesunate+sulphadoxine-pyrimethamineDihydroartemisinin+piperaquine*
EIJKMAN INSTITUTE
Chloroquine (CQ)
• 4-aminoquinoline
• Chemical structure : CQ = Amodiaquine (AQ)= Piperaquine (PPQ) (Tarning 2007)
• CQ, AQ and PPQ bind with free-haem andinhibit hemozoin formation
• 4-aminoquinoline
• Chemical structure : CQ = Amodiaquine (AQ)= Piperaquine (PPQ) (Tarning 2007)
• CQ, AQ and PPQ bind with free-haem andinhibit hemozoin formation
Piperaquine
EIJKMAN INSTITUTE
Mechanism for the antimalarial drugresistance (Borst and Ouellette, 1995)
a. Alteration in drug transportQuinoline antimalarialsArtemisinin (?)
b. Alteration in binding affinity to enzymeAntifolates, Sulpha drugs,Coenzyme Q analogues such as atovaquoneArtemisinin (?)
EIJKMAN INSTITUTE
a. Alteration in drug transportQuinoline antimalarialsArtemisinin (?)
b. Alteration in binding affinity to enzymeAntifolates, Sulpha drugs,Coenzyme Q analogues such as atovaquoneArtemisinin (?)
CtFV
Hemoglobin degradation pathways
EIJKMAN INSTITUTE
n
FV
Molecular basis of parasite resistanceto quinoline antimalarials
¤ Resistant-parasites accumulate less chloroquine
Resistance is reversed by Ca-channel blockers (Similar to multi-drug resistance in cancer cells, mdr gene: ATP-dependent drugeffluxer)
¤ Identification of P-glycoprotein homologue (PfPgh1) in themalaria parasite that is encoded pfmdr1 gene (Foote et al, 1989)
Identification of pfcrt gene and its product, pfCRT, a transporterprotein localized to food vacuole (Fidock et al, 2000)
¤ Multifactorial mechanisms?
¤ Resistant-parasites accumulate less chloroquine
Resistance is reversed by Ca-channel blockers (Similar to multi-drug resistance in cancer cells, mdr gene: ATP-dependent drugeffluxer)
¤ Identification of P-glycoprotein homologue (PfPgh1) in themalaria parasite that is encoded pfmdr1 gene (Foote et al, 1989)
Identification of pfcrt gene and its product, pfCRT, a transporterprotein localized to food vacuole (Fidock et al, 2000)
¤ Multifactorial mechanisms?
EIJKMAN INSTITUTE
Topology and function of the Plasmodiumfalciparum chloroquine resistance transporter
(PfCRT)
Sanchez et al, 2010
EIJKMAN INSTITUTE
K76T is used as molecular markers for chloroquine resistance in P. falciparum fieldisolates. The 76T allelic distribution declines significantly in Malawi whenchloroquine was replaced with SP in 1993Their roles in P. vivax and P. chabaudi were not proven. Other modulatory factor(s)?
Topology and function of thePlasmodium falciparum Multi drug resistance 1
(PfMDR1)
Sanchez et al, 2010
EIJKMAN INSTITUTE
Allelic replacement experiment (Reed et al, 2000) of 184F,1034C, 102D and 1246Y confers resistance to CQ andmodulate sensitivity to QN, MF, HF and ART
Topology and function of the Plasmodium falciparumMulti drug resistance-associated Protein 1 (PfMRP1)
Sanchez et al, 2010
EIJKMAN INSTITUTE
Polymorphisms in the pvCRTand its corresponding sites at pvCRT-o
EIJKMAN INSTITUTE
Polymorphisms in the pvMDR1and its corresponding sites at pfMDR1-o
Orjuela-Sanches et al. AAC 2009
EIJKMAN INSTITUTE
Located on chromosome 8
Map of pppk-dhps geneof the malaria parasite
nt1784pppk
dhpsPfF3717 PfR186
PfJR82 PfRJR83
PfR199
PfFJR84 PfRJR85
PfF153 Pf165R
dhps
RFLP analysisMspA1I for S436F/AAva II for A437GFok I for K540EBstU1I and Bsl1 for A581GMwoI for A613S/T
L L’
EIJKMAN INSTITUTE
437G is the most common allele
Chromosome 4
DHFR Junction TS
1875 bp
Map of the dhfr-ts gene of the malarialparasite
EIJKMAN INSTITUTE
108N is the most common allele108T+16V confers resistance to Cycloguanilbut retains sensitivity to Pyrimethamine
DHFR Junction
JR78 JR79JR77JR76
Restriction enzymesNlaIII for 16ValTai I and Mae II for 50ArgTsp5091 for 51IleXmnI for 59ArgBsrI for 108Asn, ScrfI for 108ThrAlu I for Ser108
CO I
CO III
Cytb
6kb
Extrachromosomal genomesin the malarial parasites
EIJKMAN INSTITUTE
Predicted Secondary Structure of the putativeapocytochrome b of Plasmodium berghei
Cytoplasmic
H HGVFL
AS
RY
SP
EIS
YA YY S I Q H I LRE
LWS
GW
CF R
YMA T F
I GYVLPWGQ
MS
YW
GA
TV
I
TN
LL
SG
I
PS
LV
IW L C
GG
YT
VSDPT
IKR
FFVF G V I PL
SH
PD
NA
IV
VN
TY
V TP
LQ I V P
EWY
FLPFYAML
P
KT
I
SKNAGL VI IG C Q L
P Q DIFI
L YG
QoQo
L
50
250
M133I
L144S
V284F
G131, N245, F264 MucidinI141, T142 StigmatellinF123, G131, G137, MyxothiazolY268N
Y268C M133, L144, I258, F267,Y268, L271, K272, P275,G280, L283, V284AtovaquoneH H
H
N
MN
YNSINLVKTHLIN
YPC
PL N I NF LWN
YG
FL LGI I
F FIQ ILT
GVFL M
A TGA SLVF FLT YLHI
LRGLN
YS Y
LYL
PL
SW I S GL I IF A L FI V TA F
I GY
L I F
AV FP
I C L
I F V
F F I
LH
LH
SGT
NP
L G Y D T A L K I P F YP
NL
LS
LD
VK
GF
NN IL I LF L I QS IFG V IL GL VIV IASL QLL FLL
A
EQ
RN
LT
TI
IQ
F KMVF
SA
RE
YS
FPI I
W FMC SF Y A LL W IG C Q L YGR LFII LFF SSGL FSL
VQ
KK T H YD
YSS
QANI
MatrixQi
QiNH2
COO-
L
N27, G33, L217 Antimycin AI14, L215 Diuron
100
200
300
M133, L144, I258, F267,Y268, L271, K272, P275,G280, L283, V284Atovaquone
EIJKMAN INSTITUTE
1. Budimulja et al, 1997. Mol. Biochem. Parasitol, 84:137-141.2. Syafruddin et al 1999. Mol Biochem. Parasitol, 104:185-194.3. Siregar et al, 2008. 2008. Parasitol Int, 57:229-232.
Genotyping of malaria parasites isolatesin Indonesia using drug resistant alleles
Source: Syafruddin et al, 2005
Genotypic patterns of P. falciparum isolates in Western Indonesia
Source: Syafruddin et al, 2005
Genotypic patterns of P. falciparum isolates in Eastern Indonesia
Source: Syafruddin et al, 2005
AllelicCombination
Prevalence (%)
Wet Season Dry Season
Genotypic Profile of P. falciparum isolates inWest Sumba District and its association to
antimalarial drug resistance
CQ Resistance 76T + 86 Y 23.6(41/174*)
24.73(24/174)
76T + 1042D 65.4(125/191)
24.1 (42/174)
SP Resistance 108N/T + 51I+ 59R
0 (99) 0 (73)
437G + 540E 0 (92) 0 (92)
Source: Asih et al, 2009, Malaria J
Gene Allele Prevalence (%)Wet Season Dry Season
Pfcrt 76T 92.9 (198/213*) 84.9 (147/174)
Pfmdr1 copy number ≥ 1 - 24.1 (43/178) 42.6 (23/54)
Pfmdr1 86Y 44.3 (51/115) 40,32 (25/62)1034C 0 (0/191) 0 (0/191)1042D 72.8 (139/191) 53.3 (96/180)1246Y 0 (0/191) 0 (0/191)
Allelic frequency of genes associated with chloroquineresistance among P. falciparum isolates in West Sumba
Source: Asih et al, 2009, Malaria J
EIJKMAN INSTITUTE
Asih et al, IJP, 2010
Haplotypes of the P. vivax isolates insevere malaria cases in Papua
Haplotype Gene FrequencyPercentage
(%) (n= 94)Pvdhfr Pvdhps
A I13/57L/58R/61M/117T 383G/A553 48 51.1B I13/57L/58R/61M/117T A383/A553 30 31.9C I13/F57/58R/61M/117T 383G/A553 5 5.3C I13/F57/58R/61M/117T 383G/A553 5 5.3D I13/F57/58R/61M/117T A383/A553 1 1.1E I13/57L/58R/61M/117N 383G/A553 3 3.2F I13/57L/58R/61M/117N A383/A553 2 2.1G I13/F57/58R/61M/117N 383G/A553 4 4.3H I13/F57/58R/61M/117N A383/A553 5 5.3I I13/57L/58R/T61/117T 383G/A553 1 1.1J I13/57L/S58/61M/117T A383/A553 1 1.1K I13/57L/58R/T61/117N 383G/A553 2 2.1L I13/57L/58R/61M/117N 383G/A553 2 2.1M I13/57L/58R/61M/117S 383G/A553 4 4.3N I13/57L/58R/T61/117S 383G/A553 4 4.3
EIJKMAN INSTITUTE
Does Artemisinin-resistant parasite emergein Indonesia?
Does Artemisinin-resistant parasite emergein Indonesia?
EIJKMAN INSTITUTE
Source: Asih et al, 2009, Am J Trop MedEIJKMAN INSTITUTE
Parasite clearance day prolonged after treatment withArtemisinin-based Combination Therapy (ACT)
Source: Asih et al, 2009, Am J Trop Med
EIJKMAN INSTITUTE
AS+AQ or DHP is given in three days (D0, D1 and D2)
Conclusions1. Molecular assays indicated that multi drug-resistant
strains of malarial parasites has been emerging inIndonesia
2. ACTs showed high efficacy againsts uncomplicatedmalaria in Indonesia but early sign of reduced efficacy invivo has been detected
3. Appropriate use of ACTs and regular monitoring usingdrug sensitivity test in vivo and molecular markers shouldbe performed to contain or delay the spread of artemisinin-resistant parasites
Conclusions1. Molecular assays indicated that multi drug-resistant
strains of malarial parasites has been emerging inIndonesia
2. ACTs showed high efficacy againsts uncomplicatedmalaria in Indonesia but early sign of reduced efficacy invivo has been detected
3. Appropriate use of ACTs and regular monitoring usingdrug sensitivity test in vivo and molecular markers shouldbe performed to contain or delay the spread of artemisinin-resistant parasites
EIJKMAN INSTITUTE
National Institute of Health, Research and Development,The Ministry of Health (LITBANGKES)/United States Naval MedicalResearch Unit 2 (NAMRU-2), JakartaSekartutiRita MarletaWilliam O Rogers
UMCN, Nijmegen, The NetherlandsRW SauerweinAJAM van der Ven
Collaborating InstitutionsEijkman Institute for Molecular BiologyDin SyafruddinFarah CoutrierPuji BS AsihSangkot MarzukiJosephine E Siregar
National Institute of Health, Research and Development,The Ministry of Health (LITBANGKES)/United States Naval MedicalResearch Unit 2 (NAMRU-2), JakartaSekartutiRita MarletaWilliam O Rogers
UMCN, Nijmegen, The NetherlandsRW SauerweinAJAM van der Ven
EIJKMAN INSTITUTE
Thank you
Funding Sources
EIJKMAN INSTITUTE
Thank you